Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Benner

Showing results (331-340 of 347) with videos related to

Pageof 35
Sort By:
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Leukemia|January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsJacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
Leukemia|January 14, 2026
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY studyAlberto Hernández-Sánchez, Ángela Villaverde Ramiro, Eric Sträng, et al.
Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.
The Lancet. Haematology|May 15, 2023
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trialHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood|December 28, 2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialSilke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2020
Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer PrognosisSonja Neumeyer, Xinwei Hua, Petra Seibold, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Cancer Cell|August 16, 2011
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymomaHendrik Witt, Stephen C Mack, Marina Ryzhova, et al.
Pageof 35

Showing results (331-340 of 347) with videos related to

Sort By:
Pageof 35
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Leukemia|January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsJacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
Leukemia|January 14, 2026
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY studyAlberto Hernández-Sánchez, Ángela Villaverde Ramiro, Eric Sträng, et al.
Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.
The Lancet. Haematology|May 15, 2023
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trialHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood|December 28, 2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialSilke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2020
Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer PrognosisSonja Neumeyer, Xinwei Hua, Petra Seibold, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Cancer Cell|August 16, 2011
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymomaHendrik Witt, Stephen C Mack, Marina Ryzhova, et al.
Pageof 35